Synlogic Reminds Stockholders of 2023 Annual General Meeting Details
08 6월 2023 - 7:45PM
Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing
therapeutics based on synthetic biology, today reminded
stockholders that it will hold its 2023 Annual General Meeting of
Stockholders on Thursday, June 15, 2023 at 8:00 a.m. EST. The
Annual Meeting will be held in a virtual meeting format only.
Stockholders can access the meeting here, vote
their shares electronically and submit their questions by entering
their 16-digit control number found on the Notice of Internet
Availability or the proxy card that they previously received via
mail and email. Stockholders should allow ample time for check-in
procedures before the meeting begins.
Whether or not stockholders plan to virtually attend the Annual
Meeting, Synlogic urges them to vote and submit their
proxy in advance of the Annual Meeting by one of the methods
described in the proxy materials for the Annual Meeting.
About Synlogic
Synlogic is a clinical-stage biotechnology company advancing
novel, oral, non-systemically absorbed biotherapeutics to transform
the care of serious diseases in need of new treatment options. The
Company’s late-stage pipeline is focused on rare metabolic
diseases, led by SYNB1934, currently being studied as a potential
treatment for phenylketonuria (PKU) in Synpheny-3, a global,
pivotal Phase 3 study. Additional product candidates address
diseases including homocystinuria (HCU), enteric hyperoxaluria,
gout, and cystinuria. This pipeline is fueled by the Synthetic
Biotic platform, which applies precision genetic engineering to
well-characterized probiotics. This enables Synlogic to create
GI-restricted, oral medicines designed to consume or modify
disease-specific metabolites – an approach well suited for PKU and
HCU, both inborn errors of metabolism, as well as other disorders
in which the disease–specific metabolites transit through the GI
tract, providing validated targets for these Synthetic Biotics.
Research activities include a partnership with Roche focused on
inflammatory bowel disease (IBD), and a collaboration with Ginkgo
Bioworks in synthetic biology, which has contributed to two
pipeline programs to date. For more information, please visit
www.synlogictx.com or follow us on Twitter or LinkedIn.
Forward-Looking Statements
This press release contains "forward-looking statements" that
involve substantial risks and uncertainties for purposes of the
safe harbor provided by the Private Securities Litigation Reform
Act of 1995. All statements, other than statements of historical
facts, included in this press release regarding strategy, future
operations, clinical development plans, future financial position,
future revenue, projected expenses, prospects, plans and objectives
of management are forward-looking statements. In addition, when or
if used in this press release, the words "may," "could," "should,"
"anticipate," "believe," “look forward,” "estimate," "expect,"
"intend," on track,” "plan," "predict," “prepare” and similar
expressions and their variants, as they relate to Synlogic,
may identify forward-looking statements. Examples of
forward-looking statements, include, but are not limited to,
statements regarding the potential of Synlogic's approach
to Synthetic Biotics to develop therapeutics to address a wide
range of diseases including: inborn errors of metabolism and
inflammatory and immune disorders; our expectations about
sufficiency of our existing cash balance; the future clinical
development of Synthetic Biotics; the
approach Synlogic is taking to discover and develop novel
therapeutics using synthetic biology; and the expected timing
of Synlogic's clinical trials of SYNB1934, SYNB1353,
SYNB8802 and SYNB2081 and availability of clinical trial data.
Actual results could differ materially from those contained in any
forward-looking statements as a result of various factors,
including: the uncertainties inherent in the clinical and
preclinical development process; the ability
of Synlogic to protect its intellectual property rights;
and legislative, regulatory, political and economic developments,
as well as those risks identified under the heading "Risk Factors"
in Synlogic's filings with the U.S. Securities and
Exchange Commission. The forward-looking statements contained in
this press release reflect Synlogic's current views with
respect to future events. Synlogic anticipates that
subsequent events and developments will cause its views to change.
However, while Synlogic may elect to update these
forward-looking statements in the
future, Synlogic specifically disclaims any obligation to
do so. These forward-looking statements should not be relied upon
as representing Synlogic's view as of any date subsequent
to the date hereof.
Media Contact:
media@synlogictx.comInvestor Relations:
investor@synlogictx.com
Synlogic (NASDAQ:SYBX)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Synlogic (NASDAQ:SYBX)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024